Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of nipocalimab in pregnancies at risk for severe HDFN
MOH_2023-11-14_012805Phase 3Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Erythroblastosis fetalis (HDFN) comparing Nipocalimab with Placebo (2 arms). Started Sep 2023; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
Erythroblastosis fetalis (HDFN)
Beyond the preview
Go deeper on MOH_2023-11-14_012805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-14_012805.